| 12.35 -0.89 (-6.72%) | 05-15 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 16.57  |
1-year : | 17.9 |
| Resists | First : | 14.18 |
Second : | 15.32 |
| Pivot price | 13.4 |
|||
| Supports | First : | 12.34 |
Second : | 10.26 |
| MAs | MA(5) : | 13.32 |
MA(20) : | 13.6 |
| MA(100) : | 14.81 |
MA(250) : | 12.92  |
|
| MACD | MACD : | -0.3 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 25.1 |
D(3) : | 38.6 |
| RSI | RSI(14): 35.2 |
|||
| 52-week | High : | 19.11 | Low : | 5.46 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ EYPT ] has closed below the lower bollinger band by 17.7%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ EYPT ] is to continue within current trading range. It is unclear right now based on current values. 59.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 6 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 13.11 - 13.2 | 13.2 - 13.27 |
| Low: | 12.11 - 12.23 | 12.23 - 12.32 |
| Close: | 12.19 - 12.35 | 12.35 - 12.47 |
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.
Thu, 14 May 2026
EyePoint Pharmaceuticals stock (US30233B1098): Phase 3 trials clear third safety review - AD HOC NEWS
Tue, 12 May 2026
Mizuho Securities Reaffirms Their Buy Rating on EyePoint Pharmaceuticals (EYPT) - The Globe and Mail
Sat, 02 May 2026
Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Thu, 05 Mar 2026
EyePoint: The 'Pre-Readout' Surge Is Hiding A Commercial Reality Check (NASDAQ:EYPT) - Seeking Alpha
Wed, 04 Mar 2026
EYEPOINT PHARMACEUTICALS ($EYPT) Releases Q4 2025 Earnings - Quiver Quantitative
Mon, 02 Feb 2026
How Eyepoint Pharmaceuticals Inc. (EYPT) Affects Rotational Strategy Timing - Stock Traders Daily
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 84 (M) |
| Shares Float | 66 (M) |
| Held by Insiders | 3.6 (%) |
| Held by Institutions | 105.2 (%) |
| Shares Short | 13,660 (K) |
| Shares Short P.Month | 12,480 (K) |
| EPS | -3.18 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.4 |
| Profit Margin | 0 % |
| Operating Margin | -450.7 % |
| Return on Assets (ttm) | -38.9 % |
| Return on Equity (ttm) | -72.2 % |
| Qtrly Rev. Growth | 161.6 % |
| Gross Profit (p.s.) | -2.25 |
| Sales Per Share | 0.37 |
| EBITDA (p.s.) | -2.88 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -240 (M) |
| Levered Free Cash Flow | -148 (M) |
| PE Ratio | -3.9 |
| PEG Ratio | 0 |
| Price to Book value | 30.87 |
| Price to Sales | 32.99 |
| Price to Cash Flow | -4.32 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|